北京大学学报（医学版）2012，Vol.44Issue(2)：182-187,6.DOI:10.3969/j.isan.1671-167X.2012.02.005
我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查
Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China
摘要
Abstract
Objective:To investigate the current status of tumor necrosis factor (TNF) inhibitors application in rheumatoid arthritis (RA) patients in China and to analyze the related factors. Methods: A retrospective survey was conducted in 21 hospitals from different parts of China. The patients with RA were randomly enrolled. Data of their social backgrounds, clinical conditions, usage and adverse effects of TNF inhibitors were collected. The costs of TNF inhibitors and the indirect costs of the disease were calculated. A multivariate Logistic regression analysis was performed to analyze the factors related to TNF inhibitors application. Results: In the study, 1 095 RA patients from July 2009 to November 2010 were enrolled, of whom 112 had received TNF inhibitors, representing 10.2% of the total patients. The patients who received etanercept and infliximab were 7.4% (86/1 095) of the patients and 2.4% (26/ 1 095 ) , respectively. There were 0. 5% of the patients (5/1 095) who had received both of the TNF inhibitors. The patients who had accepted etanercept and treatment duration for less than 3 months and 3 -6 months accounted for 38. 5% and 25. 0% respectively, while those treated with Infliximab were 38. 1 %. Their health assessment question-naire ( HAQ) scores were 1. 1, 0. 5 and 0. 1, corresponding to treatment duration of infliximab for less than 3,3-6 and 6-9 months and those were 1.3, 1.0, 0.3 corresponding to treatment duration of etanercept, respectively. Infliximab costs were RMB 24 525. 0, 69 300.0 and 96 800. 0 Yuan and etanercept costs were RMB 7 394. 8, 9 158. 6, 54 910. 9 Yuan, respectively. Indirect costs for RA patients who accepted infliximab for less than 3,3-6 and 6-9 months were RMB 365.6, 0 and 158.9 Yuan and those who accepted etanercept were RMB 2 158.4, 288.5 and 180. 1 Yuan, respectively. Allergy and infection were the main side-effects of etanercept and both happened in 3.5% of all the patients. Liver damage happened in 2. 3% of all the patients, while allergy and infection happened in 6. 5% of all the patients who accepted infliximab. Logistic regression analysis showed that patients with higher education experience increased the odds of entering the TNF inhibitors group (OR: 1.292, 95%67: 1. 132 -1.473, P= 0.000). Conclusion; About one-tenth of RA patients in China have accepted TNF inhibitors. Higher education experience is the key factor for using TNF inhibitors.关键词
关节炎,类风湿/肿瘤坏死因子/问卷调查/药费支出Key words
Arthritis, rheumatoid/ Tumor necrosis factor-alpha/ Questionnaires/ Drug costs分类
医药卫生引用本文复制引用
王秀茹,王莉枝,王永福,杨荣,王国春,卢昕,朱平,陈丽娜,王轶,王晓元,靳洪涛,苏茵,刘金婷,陈海英,魏平,王俊祥,刘湘源,孙琳,崔刘福,舒荣,刘白鹭,张卓莉,安媛,李光韬,李振彬,杨静,李俊芳,贾彬,张风肖,陶杰梅,林金盈,韦美秋,刘晓敏,周云杉,柯丹,胡绍先,叶丛,韩淑玲,杨岫岩,李昊,黄慈波,高明,赖蓓,李兴福,张晓盈,宋立军,穆荣,栗占国,段天骄,朱佳鑫,李小峰,王彩虹..我国类风湿关节炎患者应用肿瘤坏死因子抑制剂现况调查[J].北京大学学报（医学版）,2012,44(2):182-187,6.基金项目
十一五"国家科技支撑计划项目(20008BA159B01)资助 （20008BA159B01）
